All In Biotech

Drug Trial Radar · NCT07551427

A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

A Phase II, Single-arm, Open-label, Multicenter Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Jun 18, 2026

Primary completion

Jun 2028

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to guide dosing. Cohort 2 evaluates the efficacy and safety of TQ05105 in participants with intermediate/high-risk myelofibrosis who are refractory, relapsed, or intolerant to prior Janus kinase (JAK) inhibitor therapy.

Conditions

  • Myelofibrosis

Interventions

  • TQ05105 Tablets (Rovadicitinib Tablets)Drug

    TQ05105 is an inhibitor of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing protein kinase 1 (ROCK1) and 2 (ROCK2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with ≥35% reduction in spleen volume from baseline at week 24 (SVR35)Time frame: up to 24 weeks
  2. Peak concentration (Cmax)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  3. Time to peak concentration (Tmax)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  4. Elimination half-life (t1/2)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  5. Area under the curve from time 0 to last measurable concentration (AUC0-t)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  6. Area under the curve from time 0 to infinity (AUC0-∞)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  7. Total clearance (CLt)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  8. Renal clearance (CLr)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  9. Apparent volume of distribution (Vd/F)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)
  10. Elimination rate constant (λz)Time frame: Pre-dose on Cycle 1 Day 1 and Day 7; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 1; and 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Cycle 1 Day 7. (28 days a cycle)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • Guangzhou First Municipal People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Cangzhou People's Hospital rovince

    Cangzhou, Hebei, China · Recruiting

  • Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China · Recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Xingtai People's Hospital

    Xingtai, Hebei, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, China · Recruiting

  • Union Hospital Tongji College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjin, Jiangsu, China · Recruiting

  • Jiangsu Provincial Hospital of Traditional Chinese Medicine

    Nanjing, Jiangsu, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China · Recruiting

  • The First Affiliated Hospital of Air Force Medical University

    Xi'an, Shaanxi, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Heping Hospital Affiliated To Changzhi Medical College

    Changzhi, Shanxi, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • Chinese Academy of Medical Sciences Hematology Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.